Rocket Pharmaceuticals Quarterly Balance Sheets Chart
Quarterly
|
Annual
Rocket Pharmaceuticals Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||||||||||||||||||||||||
| current assets: | |||||||||||||||||||||||||||||||||||||||
| cash and cash equivalents | 32,819,000 | 49,810,000 | 163,635,000 | 65,599,000 | 38,607,000 | 35,276,000 | 55,904,000 | 225,657,000 | 45,076,000 | 64,579,000 | 140,517,000 | 196,669,000 | 187,548,000 | 130,552,000 | 232,694,000 | 245,644,000 | 264,608,000 | 252,540,000 | 82,226,000 | 163,203,000 | 190,520,000 | 89,195,000 | 64,833,000 | 124,464,000 | 38,076,000 | 52,548,000 | 171,136,000 | 78,720,000 | 49,146,000 | 27,610,000 | 25,273,000 | 29,798,000 | 83,004,000 | 38,519,000 | 58,706,000 | 89,248,000 | 49,012,000 | 53,139,000 | 3,618,000 |
| investments | 238,675,000 | 268,354,000 | 208,701,000 | 170,063,000 | 240,218,000 | 295,037,000 | 317,271,000 | 211,514,000 | 261,964,000 | 266,505,000 | 215,877,000 | 109,865,000 | 133,820,000 | 216,041,000 | 156,046,000 | 175,815,000 | 162,222,000 | 213,813,000 | 146,464,000 | 86,600,000 | 85,375,000 | 151,366,000 | 192,950,000 | 72,126,000 | 89,402,000 | 79,555,000 | |||||||||||||
| prepaid expenses and other current assets | 5,661,000 | 6,329,000 | 5,847,000 | 6,092,000 | 13,900,000 | 14,846,000 | 5,047,000 | 9,694,000 | 5,034,000 | 6,949,000 | 7,666,000 | 4,597,000 | 4,403,000 | 7,255,000 | 3,319,000 | 3,610,000 | 3,596,000 | 1,033,000 | 747,000 | 1,067,000 | 1,928,000 | 1,876,000 | 1,341,000 | 480,000 | 982,000 | 859,000 | 465,000 | 301,000 | 52,000 | ||||||||||
| total current assets | 277,155,000 | 324,493,000 | 378,183,000 | 241,754,000 | 292,725,000 | 345,159,000 | 378,222,000 | 446,865,000 | 312,074,000 | 338,033,000 | 364,060,000 | 311,131,000 | 325,771,000 | 353,848,000 | 392,059,000 | 425,069,000 | 430,426,000 | 471,822,000 | 233,214,000 | 255,436,000 | 279,805,000 | 245,591,000 | 263,629,000 | 199,619,000 | 128,821,000 | 134,608,000 | 184,828,000 | 101,047,000 | 103,872,000 | 109,821,000 | 116,633,000 | 128,349,000 | 138,924,000 | 98,702,000 | 103,247,000 | 119,224,000 | 49,477,000 | 53,440,000 | 3,670,000 |
| property and equipment | 32,524,000 | 34,565,000 | 36,786,000 | 38,514,000 | 39,548,000 | 39,337,000 | 39,172,000 | 36,534,000 | 32,986,000 | 30,588,000 | 29,009,000 | 25,613,000 | 24,851,000 | 24,354,000 | 22,299,000 | 22,090,000 | 20,989,000 | 19,833,000 | 15,803,000 | 14,314,000 | 11,140,000 | 19,270,000 | 9,844,000 | 7,077,000 | 1,245,000 | 976,000 | 1,146,000 | 563,000 | 615,000 | 1,076,000 | 1,122,000 | 1,130,000 | 1,045,000 | 976,000 | 790,000 | 756,000 | 29,000 | ||
| goodwill | 39,154,000 | 39,154,000 | 39,154,000 | 39,154,000 | 39,154,000 | 39,154,000 | 39,154,000 | 39,154,000 | 39,154,000 | 39,154,000 | 39,154,000 | 30,815,000 | 30,815,000 | 30,815,000 | 30,815,000 | 30,815,000 | 30,815,000 | 30,815,000 | 30,815,000 | 30,815,000 | 30,815,000 | 30,815,000 | 30,815,000 | 30,815,000 | 30,815,000 | 30,815,000 | 30,815,000 | ||||||||||||
| intangible assets | 25,150,000 | 25,150,000 | 25,150,000 | 25,150,000 | 25,150,000 | 25,150,000 | 25,150,000 | 25,150,000 | 25,724,000 | 25,724,000 | 25,724,000 | ||||||||||||||||||||||||||||
| restricted cash | 1,365,000 | 1,362,000 | 1,362,000 | 1,362,000 | 1,362,000 | 1,362,000 | 1,372,000 | 1,372,000 | 1,362,000 | 1,340,000 | 1,340,000 | 1,354,000 | 1,343,000 | 1,343,000 | 1,343,000 | 1,334,000 | 1,334,000 | 1,461,000 | 1,568,000 | 1,525,000 | 1,525,000 | 1,525,000 | 1,525,000 | 1,525,000 | 1,645,000 | 1,644,000 | 208,000 | ||||||||||||
| deposits | 515,000 | 514,000 | 529,000 | 503,000 | 481,000 | 533,000 | 533,000 | 542,000 | 542,000 | 459,000 | 608,000 | 455,000 | 455,000 | 455,000 | 455,000 | 455,000 | 455,000 | 455,000 | 455,000 | 455,000 | 455,000 | 455,000 | 455,000 | 455,000 | 455,000 | 168,000 | 168,000 | ||||||||||||
| operating lease right-of-use assets | 3,830,000 | 4,003,000 | 4,173,000 | 4,349,000 | 4,551,000 | 4,768,000 | 3,901,000 | 4,089,000 | 4,345,000 | 4,369,000 | 1,972,000 | 1,022,000 | 1,207,000 | 1,390,000 | 1,569,000 | 1,467,000 | 1,628,000 | 1,787,000 | 1,094,000 | 1,270,000 | 1,470,000 | 2,254,000 | 2,452,000 | 2,647,000 | |||||||||||||||
| finance lease right-of-use asset | 41,286,000 | 41,825,000 | 42,363,000 | 42,902,000 | 43,440,000 | 43,979,000 | 44,517,000 | 45,056,000 | 45,594,000 | 46,133,000 | 46,664,000 | 46,875,000 | 47,410,000 | 47,945,000 | 48,480,000 | 49,011,000 | 49,507,000 | 50,311,000 | 52,547,000 | 49,250,000 | 47,541,000 | ||||||||||||||||||
| total assets | 420,979,000 | 471,066,000 | 527,700,000 | 393,688,000 | 446,411,000 | 499,442,000 | 566,341,000 | 598,762,000 | 461,781,000 | 514,757,000 | 551,807,000 | 417,265,000 | 431,852,000 | 460,150,000 | 497,020,000 | 530,241,000 | 535,154,000 | 576,484,000 | 335,496,000 | 353,065,000 | 372,751,000 | 299,910,000 | 308,720,000 | 242,138,000 | 194,981,000 | 207,574,000 | 217,165,000 | 101,778,000 | 104,655,000 | 111,065,000 | 117,923,000 | 129,647,000 | 140,139,000 | 99,851,000 | 104,207,000 | 120,124,000 | 51,688,000 | 55,526,000 | 5,520,000 |
| liabilities and stockholders' equity | |||||||||||||||||||||||||||||||||||||||
| current liabilities: | |||||||||||||||||||||||||||||||||||||||
| accounts payable and accrued expenses | 40,505,000 | 32,435,000 | 37,827,000 | 37,133,000 | 34,733,000 | 30,085,000 | 45,789,000 | 30,624,000 | 31,353,000 | 28,609,000 | 36,660,000 | 27,823,000 | 21,840,000 | 20,031,000 | 19,615,000 | 22,008,000 | 17,884,000 | 33,168,000 | 24,830,000 | 18,245,000 | 18,819,000 | 21,246,000 | 14,168,000 | 19,680,000 | 9,765,000 | 8,285,000 | 4,762,000 | ||||||||||||
| operating lease liabilities, current | 1,010,000 | 1,006,000 | 1,001,000 | 1,005,000 | 1,033,000 | 1,064,000 | 925,000 | 1,079,000 | 1,233,000 | 849,000 | 773,000 | 634,000 | 737,000 | 838,000 | 863,000 | 804,000 | 792,000 | 683,000 | 728,000 | 819,000 | 817,000 | 935,000 | 913,000 | 892,000 | |||||||||||||||
| finance lease liability, current | 1,884,000 | 1,870,000 | 1,856,000 | 1,842,000 | 1,826,000 | 1,808,000 | 1,791,000 | 1,773,000 | 1,760,000 | 1,748,000 | 1,736,000 | 1,724,000 | 1,712,000 | 1,701,000 | 1,689,000 | 1,677,000 | 1,666,000 | 1,655,000 | |||||||||||||||||||||
| total current liabilities | 43,399,000 | 35,311,000 | 40,684,000 | 39,980,000 | 37,592,000 | 32,957,000 | 48,505,000 | 33,476,000 | 34,346,000 | 31,206,000 | 39,169,000 | 30,181,000 | 24,289,000 | 22,570,000 | 22,167,000 | 24,489,000 | 25,444,000 | 40,492,000 | 31,955,000 | 20,685,000 | 21,114,000 | 22,181,000 | 15,081,000 | 20,572,000 | 10,294,000 | 10,146,000 | 7,337,000 | 4,070,000 | 3,767,000 | 4,016,000 | 5,268,000 | 7,212,000 | 5,944,000 | 4,071,000 | 4,614,000 | 3,243,000 | 2,452,000 | 2,457,000 | 7,220,000 |
| operating lease liabilities, non-current | 2,928,000 | 3,095,000 | 3,258,000 | 3,413,000 | 3,565,000 | 3,714,000 | 2,973,000 | 2,990,000 | 3,074,000 | 3,506,000 | 1,088,000 | 492,000 | 606,000 | 719,000 | 905,000 | 891,000 | 1,096,000 | 1,299,000 | 599,000 | 706,000 | 917,000 | 1,691,000 | 1,933,000 | 2,169,000 | |||||||||||||||
| finance lease liability, non-current | 19,380,000 | 19,381,000 | 19,383,000 | 19,382,000 | 19,374,000 | 19,363,000 | 19,353,000 | 19,341,000 | 19,319,000 | 19,294,000 | 19,269,000 | 19,242,000 | 19,210,000 | 19,176,000 | 19,144,000 | 19,109,000 | 19,070,000 | ||||||||||||||||||||||
| other liabilities | 1,061,000 | 1,141,000 | 1,141,000 | 1,142,000 | 1,245,000 | 1,906,000 | 2,936,000 | 1,869,000 | 2,072,000 | 1,875,000 | 2,595,000 | 37,000 | 51,000 | 65,000 | 80,000 | 94,000 | 107,000 | 122,000 | 23,000 | 23,000 | 23,000 | 23,000 | 22,000 | 23,000 | |||||||||||||||
| total liabilities | 66,768,000 | 58,928,000 | 64,466,000 | 63,917,000 | 61,776,000 | 57,940,000 | 73,767,000 | 57,676,000 | 58,811,000 | 55,881,000 | 62,121,000 | 49,952,000 | 44,156,000 | 42,530,000 | 42,296,000 | 44,583,000 | 45,717,000 | 96,485,000 | 93,655,000 | 86,542,000 | 86,700,000 | 67,992,000 | 60,216,000 | 65,061,000 | 51,361,000 | 50,498,000 | 47,019,000 | 54,014,000 | 53,580,000 | 53,535,000 | 54,659,000 | 56,479,000 | 55,085,000 | 4,407,000 | 4,965,000 | 3,649,000 | 19,969,000 | 21,574,000 | 10,278,000 |
| commitments and contingencies | |||||||||||||||||||||||||||||||||||||||
| stockholders' equity: | |||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.01 par value, authorized 5,000,000 shares: | |||||||||||||||||||||||||||||||||||||||
| series a convertible preferred stock; 300,000 shares designated; 0 shares issued and outstanding | |||||||||||||||||||||||||||||||||||||||
| series b convertible preferred stock; 300,000 shares designated; 0 shares issued and outstanding | |||||||||||||||||||||||||||||||||||||||
| common stock | 1,079,000 | 1,068,000 | 1,065,000 | 911,000 | 910,000 | 906,000 | 903,000 | 901,000 | 805,000 | 804,000 | 791,000 | 678,000 | 658,000 | 645,000 | 645,000 | 644,000 | 634,000 | 619,000 | 552,000 | 551,000 | 551,000 | 503,000 | 503,000 | 451,000 | 398,000 | 395,000 | 394,000 | 68,000 | 272,000 | 270,000 | 270,000 | 270,000 | 269,000 | 269,000 | 264,000 | 264,000 | 163,000 | 163,000 | 10,000 |
| additional paid-in capital | 1,701,608,000 | 1,690,547,000 | 1,680,219,000 | 1,486,436,000 | 1,475,013,000 | 1,462,155,000 | 1,450,722,000 | 1,440,403,000 | 1,240,745,000 | 1,230,319,000 | 1,203,074,000 | 1,014,283,000 | 977,099,000 | 952,498,000 | 946,152,000 | 932,776,000 | 886,431,000 | 842,477,000 | 503,223,000 | 498,590,000 | 493,811,000 | 394,930,000 | 392,205,000 | 302,039,000 | 221,983,000 | 219,225,000 | 216,440,000 | 316,086,000 | 314,332,000 | 313,441,000 | 312,613,000 | 311,829,000 | 310,686,000 | 309,933,000 | 305,069,000 | 304,062,000 | 163,446,000 | 163,292,000 | 76,472,000 |
| accumulated other comprehensive income | -107,000 | -27,000 | 66,000 | 213,000 | -218,000 | -135,000 | 319,000 | 117,000 | 144,000 | 10,000 | 2,000 | 17,000 | |||||||||||||||||||||||||||
| accumulated deficit | -1,348,369,000 | -1,279,450,000 | -1,218,116,000 | -1,157,789,000 | -1,091,070,000 | -1,021,424,000 | -959,370,000 | -899,710,000 | -837,811,000 | -772,110,000 | -713,775,000 | -647,052,000 | -589,296,000 | -534,894,000 | -491,912,000 | -447,665,000 | -397,547,000 | -363,022,000 | -261,927,000 | -232,847,000 | -207,807,000 | -163,288,000 | -144,004,000 | -125,324,000 | -78,554,000 | -62,465,000 | -46,698,000 | -268,374,000 | -263,504,000 | -256,109,000 | -249,547,000 | -238,877,000 | -225,903,000 | -214,775,000 | -206,091,000 | -187,851,000 | -131,890,000 | -129,503,000 | -128,041,000 |
| total stockholders’ equity | 354,211,000 | 402,970,000 | 458,876,000 | 489,686,000 | 367,313,000 | 387,696,000 | 417,620,000 | 454,724,000 | 231,918,000 | 248,504,000 | 47,764,000 | 51,075,000 | 57,530,000 | 63,264,000 | 73,168,000 | 85,054,000 | 95,444,000 | 99,242,000 | 116,475,000 | 31,719,000 | 33,952,000 | ||||||||||||||||||
| total liabilities and stockholders’ equity | 420,979,000 | 461,781,000 | 514,757,000 | 551,807,000 | 417,265,000 | 431,852,000 | 460,150,000 | 497,020,000 | 299,910,000 | 308,720,000 | 101,778,000 | 104,655,000 | 111,065,000 | 117,923,000 | 129,647,000 | 140,139,000 | 99,851,000 | 104,207,000 | |||||||||||||||||||||
| total stockholders' equity | 412,138,000 | 463,234,000 | 329,771,000 | 384,635,000 | 441,502,000 | 492,574,000 | 541,086,000 | 485,658,000 | 489,437,000 | 479,999,000 | 241,841,000 | 266,523,000 | 286,051,000 | ||||||||||||||||||||||||||
| total liabilities and stockholders' equity | 471,066,000 | 527,700,000 | 393,688,000 | 446,411,000 | 499,442,000 | 566,341,000 | 598,762,000 | 530,241,000 | 535,154,000 | 576,484,000 | 335,496,000 | 353,065,000 | 372,751,000 | ||||||||||||||||||||||||||
| series a convertible preferred stock; 300,000 shares designated as series a; 0 shares issued and outstanding | |||||||||||||||||||||||||||||||||||||||
| series b convertible preferred stock; 300,000 shares designated as series b; 0 shares issued and outstanding | |||||||||||||||||||||||||||||||||||||||
| treasury stock | -47,000 | -47,000 | -47,000 | -76,000 | -429,000 | -344,000 | -344,000 | ||||||||||||||||||||||||||||||||
| accumulated other comprehensive loss | -508,000 | -722,000 | -90,000 | -357,000 | -596,000 | -765,000 | -629,000 | -161,000 | -97,000 | -81,000 | -75,000 | 69,000 | 229,000 | -75,000 | -89,000 | -207,000 | -79,000 | -16,000 | -25,000 | -72,000 | -72,000 | -54,000 | |||||||||||||||||
| liabilities and stockholders’ equity | |||||||||||||||||||||||||||||||||||||||
| stockholders’ equity: | |||||||||||||||||||||||||||||||||||||||
| convertible notes, net of unamortized discount, current | 5,102,000 | 4,986,000 | 4,765,000 | ||||||||||||||||||||||||||||||||||||
| convertible notes, net of unamortized discount, non-current | 35,544,000 | 42,132,000 | |||||||||||||||||||||||||||||||||||||
| prepaid expenses and other assets | 5,469,000 | 4,524,000 | 5,633,000 | 3,910,000 | 5,030,000 | 5,846,000 | 3,029,000 | 1,343,000 | 2,505,000 | 2,131,000 | |||||||||||||||||||||||||||||
| finance lease liabilities, non-current | 19,028,000 | 18,946,000 | 18,900,000 | 18,852,000 | |||||||||||||||||||||||||||||||||||
| finance lease liabilities, current | 1,632,000 | 1,621,000 | 1,478,000 | ||||||||||||||||||||||||||||||||||||
| convertible notes, net of unamortized discount | 46,228,000 | 45,794,000 | 44,097,000 | 43,180,000 | 42,297,000 | 40,629,000 | 39,842,000 | ||||||||||||||||||||||||||||||||
| series a convertible preferred stock; 300,000 shares designated as series a; 0 shares issued and outstanding at june 30, 2019 and december 31, 2018 | |||||||||||||||||||||||||||||||||||||||
| series b convertible preferred stock; 300,000 shares designated as series b; 0 shares issued and outstanding at june 30, 2019 and december 31, 2018 | |||||||||||||||||||||||||||||||||||||||
| liabilities and shareholders' equity | |||||||||||||||||||||||||||||||||||||||
| shareholders' equity: | |||||||||||||||||||||||||||||||||||||||
| preferred shares, 0.01 par value, authorized 1,000,000 shares: | |||||||||||||||||||||||||||||||||||||||
| series a convertible preferred shares; 300,000 shares designated as series a; 0 shares issued and outstanding at march 31, 2019 and december 31, 2018 | |||||||||||||||||||||||||||||||||||||||
| series b convertible preferred shares; 300,000 shares designated as series b; 0 shares issued and outstanding at march 31, 2019 and december 31, 2018 | |||||||||||||||||||||||||||||||||||||||
| total shareholders' equity | 177,077,000 | 157,076,000 | 170,146,000 | ||||||||||||||||||||||||||||||||||||
| total liabilities and shareholders' equity | 242,138,000 | 207,574,000 | 217,165,000 | ||||||||||||||||||||||||||||||||||||
| liabilities and shareholders’ equity | |||||||||||||||||||||||||||||||||||||||
| accrued research and development costs | 529,000 | 1,861,000 | 2,575,000 | ||||||||||||||||||||||||||||||||||||
| deferred rent and lease obligations | 438,000 | 510,000 | |||||||||||||||||||||||||||||||||||||
| shareholders’ equity: | |||||||||||||||||||||||||||||||||||||||
| preferred shares, 0.01 par value, authorized 1,000,000 shares series a convertible preferred shares; 300,000 shares designated as series a; 0 and 128,738 shares issued and outstanding at september 30, 2018 and december 31, 2017, respectively | |||||||||||||||||||||||||||||||||||||||
| series b convertible preferred shares; 300,000 shares designated as series b; 0 and 126,909 shares issued and outstanding at september 30, 2018 and december 31, 2017, respectively | |||||||||||||||||||||||||||||||||||||||
| total shareholders’ equity | 143,620,000 | ||||||||||||||||||||||||||||||||||||||
| total liabilities and shareholders’ equity | 194,981,000 | ||||||||||||||||||||||||||||||||||||||
| preferred shares, 0.01 par value, authorized 1,000,000 shares | |||||||||||||||||||||||||||||||||||||||
| series a convertible preferred shares; 300,000 shares designated as series a; 0 and 128,738 shares issued and outstanding at june 30, 2018 and december 31, 2017, respectively | |||||||||||||||||||||||||||||||||||||||
| series b convertible preferred shares; 300,000 shares designated as series b; 0 and 126,909 shares issued and outstanding at june 30, 2018 and december 31, 2017, respectively | |||||||||||||||||||||||||||||||||||||||
| short term investments | 11,561,000 | ||||||||||||||||||||||||||||||||||||||
| convertible notes,net of unamortized discount | 39,084,000 | ||||||||||||||||||||||||||||||||||||||
| deferred rent and lease liability | 598,000 | ||||||||||||||||||||||||||||||||||||||
| series a convertible preferred shares; 300,000 shares designated as series a; 0 and 128,738 shares issued and outstanding at march 31, 2018 and december 31, 2017, respectively | |||||||||||||||||||||||||||||||||||||||
| series b convertible preferred shares; 300,000 shares designated as series b; 0 and 126,909 shares issued and outstanding at march 31, 2018 and december 31, 2017, respectively | |||||||||||||||||||||||||||||||||||||||
| short-term investments | 21,294,000 | 53,979,000 | 81,144,000 | 89,432,000 | 96,675,000 | 54,579,000 | 59,703,000 | 43,559,000 | 29,117,000 | ||||||||||||||||||||||||||||||
| other assets | 168,000 | 168,000 | 168,000 | 168,000 | 168,000 | 170,000 | 173,000 | 170,000 | 144,000 | 2,182,000 | 2,086,000 | 1,850,000 | |||||||||||||||||||||||||||
| accounts payable | 451,000 | 383,000 | 368,000 | 1,902,000 | 1,592,000 | 1,777,000 | 921,000 | 1,376,000 | 1,709,000 | 813,000 | 1,301,000 | 1,146,000 | |||||||||||||||||||||||||||
| accrued expenses and other current liabilities | 2,373,000 | 2,900,000 | 2,423,000 | 2,886,000 | 4,416,000 | 3,716,000 | 3,150,000 | 3,238,000 | 1,534,000 | 1,273,000 | 1,052,000 | 992,000 | |||||||||||||||||||||||||||
| accrued interest | 1,246,000 | 484,000 | 1,225,000 | 480,000 | 1,204,000 | 451,000 | 366,000 | 104,000 | |||||||||||||||||||||||||||||||
| 2021 convertible notes, net of issuance costs | 49,541,000 | 49,390,000 | 49,242,000 | 49,099,000 | 48,960,000 | 48,820,000 | |||||||||||||||||||||||||||||||||
| other long-term liabilities | 403,000 | 423,000 | 277,000 | 292,000 | 307,000 | 321,000 | 336,000 | 351,000 | 406,000 | 24,000 | 24,000 | 24,000 | |||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 5,000,000 shares authorized and no shares issued or outstanding | |||||||||||||||||||||||||||||||||||||||
| liabilities, redeemable convertible preferred stock and stockholders’ equity | |||||||||||||||||||||||||||||||||||||||
| notes payable, current portion | 3,063,000 | ||||||||||||||||||||||||||||||||||||||
| convertible bridge notes | |||||||||||||||||||||||||||||||||||||||
| convertible bridge notes redemption rights derivative | |||||||||||||||||||||||||||||||||||||||
| notes payable, net of current portion | 2,550,000 | ||||||||||||||||||||||||||||||||||||||
| warrant liabilities | 482,000 | ||||||||||||||||||||||||||||||||||||||
| series aa redeemable convertible preferred stock, 0.001 par value; 0 shares authorized, issued and outstanding at september 30, 2015; 25,757,874 shares authorized and 24,057,013 shares issued and outstanding at december 31, 2014 | |||||||||||||||||||||||||||||||||||||||
| series x redeemable convertible preferred stock, 0.001 par value; 0 shares authorized, issued and outstanding at september 30, 2015; 2,902,050 shares authorized and 1,892,320 shares issued and outstanding at december 31, 2014 | |||||||||||||||||||||||||||||||||||||||
| total redeemable convertible preferred stock | 46,801,000 | ||||||||||||||||||||||||||||||||||||||
| stockholders’ equity | |||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value: 5,000,000 shares authorized and 0 shares issued or outstanding | |||||||||||||||||||||||||||||||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders’ equity | 120,124,000 | 51,688,000 | 55,526,000 | ||||||||||||||||||||||||||||||||||||
| 2020 convertible notes, net of debt discount of 12,074 | 8,926,000 | ||||||||||||||||||||||||||||||||||||||
| 2020 convertible notes derivative liability | 8,567,000 | ||||||||||||||||||||||||||||||||||||||
| series aa redeemable convertible preferred stock, 0.001 par value; 0 shares authorized, issued and outstanding at june 30, 2015; 25,757,874 shares authorized and 24,057,013 shares issued and outstanding at december 31, 2014 | |||||||||||||||||||||||||||||||||||||||
| series x redeemable convertible preferred stock, 0.001 par value; 0 shares authorized, issued and outstanding at june 30, 2015; 2,902,050 shares authorized and 1,892,320 shares issued and outstanding at december 31, 2014 | |||||||||||||||||||||||||||||||||||||||
| 2020 convertible notes, net of debt discount of 12,333 | 8,667,000 | ||||||||||||||||||||||||||||||||||||||
| 2020 convertible notes derivative | 10,426,000 | ||||||||||||||||||||||||||||||||||||||
| series aa redeemable convertible preferred stock, 0.001 par value; 0 shares authorized, issued and outstanding at march 31, 2015; and 25,757,874 shares authorized, 24,057,013 shares issued and outstanding at december 31, 2014 | |||||||||||||||||||||||||||||||||||||||
| series x redeemable convertible preferred stock, 0.001 par value; 0 shares authorized, issued and outstanding at march 31, 2015; 2,902,050 shares authorized and 1,892,320 shares issued and outstanding at december 31, 2014 | |||||||||||||||||||||||||||||||||||||||
| preferred stock. 0.001 par value: 5,000,000 shares authorized and 0 shares issued or outstanding | |||||||||||||||||||||||||||||||||||||||
| liabilities, redeemable convertible preferred stock and stockholders’ deficit | |||||||||||||||||||||||||||||||||||||||
| convertible notes payable | 1,541,000 | ||||||||||||||||||||||||||||||||||||||
| convertible notes redemption rights derivative | 480,000 | ||||||||||||||||||||||||||||||||||||||
| series aa redeemable convertible preferred stock, 0.001 par value; 25,757,874 shares authorized; 24,057,013 shares and 23,204,783 shares issued and outstanding at december 31, 2014 and 2013, respectively; | 46,253,000 | ||||||||||||||||||||||||||||||||||||||
| series x redeemable convertible preferred stock, 0.001 par value; 2,902,050 shares authorized; 1,892,320 shares issued and outstanding at december 31, 2014 and 2013; | 548,000 | ||||||||||||||||||||||||||||||||||||||
| stockholders’ deficit: | |||||||||||||||||||||||||||||||||||||||
| total stockholders’ deficit | -51,559,000 | ||||||||||||||||||||||||||||||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders’ deficit | 5,520,000 | ||||||||||||||||||||||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||||||||||||||
| research and development | -5,592,000 | ||||||||||||||||||||||||||||||||||||||
| general and administrative | -2,112,000 | ||||||||||||||||||||||||||||||||||||||
| income from operations | -7,704,000 | ||||||||||||||||||||||||||||||||||||||
| other income | |||||||||||||||||||||||||||||||||||||||
| interest expense | -980,000 | ||||||||||||||||||||||||||||||||||||||
| change in fair value of warrant liabilities and convertible notes redemption rights derivative | -847,000 | ||||||||||||||||||||||||||||||||||||||
| net income | -9,531,000 | ||||||||||||||||||||||||||||||||||||||
| net income per share | -13,520 | ||||||||||||||||||||||||||||||||||||||
| weighted-average number of shares outstanding—basic and diluted | 1,020,088,000 |
We provide you with 20 years of balance sheets for Rocket Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Rocket Pharmaceuticals. Explore the full financial landscape of Rocket Pharmaceuticals stock with our expertly curated balance sheets.
The information provided in this report about Rocket Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.